News Releases – Bausch Health Companies Inc.
Title Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024. Download PDF. Bausch Health and Salix survey highlights urgent need for improved understanding of liver disease across healthcare provider disciplines as prevalence of cirrhosis rises. Date.
News Releases - Bausch Health
Jul 24, 2024 · Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024. Read More ». 10/08/24. Bausch Health and Salix survey highlights urgent need for improved understanding of liver disease across healthcare provider disciplines as prevalence of cirrhosis rises. Read More ».
News Releases – Bausch Health Companies Inc.
Oct 11, 2024 · Title First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans. Download PDF. Bausch Health Wins DUOBRII® and BRYHALI® Patent Infringement Case. Date.
Bausch Health Enters Into Arrangement Agreement with Bausch
Apr 28, 2022 · Bausch Health Enters Into Arrangement Agreement with Bausch + Lomb Corporation in Connection with Previously Announced Proposed Separation. LAVAL, QC and VAUGHAN, ON, April 28, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that, in …
Bausch Health Continuing Process Toward Separating Bausch
Aug 22, 2022 · The separation of Bausch + Lomb is contingent on the expiry of customary lockups related to the initial public offering of Bausch + Lomb, the achievement of targeted debt leverage ratios and the receipt of applicable shareholder and other necessary approvals.
Bausch Health Companies Inc.
Oct 1, 2024 · Bausch Health Announces Final Results and Expiration of Exchange Offers and Consent Solicitations. Salix Pharmaceuticals Applauds Implementation of K76.82 – a New ICD-10 Code for Hepatic Encephalopathy. Bausch Health Companies Inc. is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better ...
Home | Bausch Health
Aug 13, 2024 · Learn about Bausch Health, a global company whose mission is to improve people’s lives with our health care products.
News Releases – Bausch Health Companies Inc.
Dec 22, 2021 · Title Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis. Download PDF. Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer. Date.
Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results
Feb 22, 2024 · Bausch Health Announces Fourth-Quarter and Full-Year 2023 Results. February 22, 2024. Fourth-Quarter revenues of $2.41 billion, up 10% on a Reported basis and up 4% on an Organic1 basis. Full-Year revenues of $8.76 billion, up …
Bausch Health Announces First-Quarter 2023 Results
May 4, 2023 · First-Quarter revenues of $1.94 billion, up 1% reported and 4% organic1. Solid revenue growth across core products, led by Xifaxan with 7% reported growth. Mid- and late-stage product pipeline advancing.